Articles from OptimizeRx Corporation

WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.

No Stockholder Action Required at this Time

Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call.

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company’s Board of Directors has retained a search firm to assist in this transition.

WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call.

WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initial program, however, ultimately resulted in a multi-solution, multi-brand engagement while DAAP conversion continues through the client’s internal review and approval process. This engagement represents an ongoing expansion of investment by a top-tier pharma client in OptimizeRx’s solutions and demonstrates the value of scaling them across several brands in its portfolio, driving stronger commercial performance from brands through HCP and DTC marketing alignment.

The availability of Micro-Neighborhood® Targeting on the Company’s Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing

–   Q2 revenue of $18.8 million, increasing 36% year-over-year–   Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%–   Won 8 DAAP deals during Q2

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call.

OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide

The Company’s AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program

• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client

WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million

WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024.

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the fourth quarter and full year ended December 31, 2023.

Market Embraces Disruptive AI-Powered Capabilities

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter.

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023.

Empowering healthcare providers to remove barriers to care

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company’s growth plans.

WALTHAM, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced select preliminary unaudited financials for 2023 and is providing the following business update.

WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that executives from the Company will be presenting and participating in one-on-ones at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.

- Increases guidance for 2023 and introduces guidance for 2024- Total revenue of $16.3 million- GAAP net loss per share of $(0.17)- Non-GAAP net income per share of $0.09- Total DAAP (fka RWD) deals for the year now stands at 16- Completed acquisition of Medicx Health after quarter end

Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer

Preannounces Preliminary Third Quarter 2023 Results

The New AI-Directed Capability Unites Point-of-Care and Traditional Digital Medias to Provide a Comprehensive Solution for Pharmaceutical Marketing

WALTHAM, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the expansion of its AI-enabled healthcare technology platform’s reach through multi-year partnerships with two leading electronic health record (EHR) providers and a telehealth platform. These partnerships are expected to be active within the platform later this year and to materially contribute to the Company’s digital point-of-care (POC) reach.

– RWD.AI-enabled portion of the core business sees 186% YOY growth during the first half of 2023

ROCHESTER, Mich., July 31, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Monday, August 14, 2023 at 4:30 p.m. Eastern Time to discuss its results for the second quarter and half year period ended June 30, 2023. The financial results will be issued in a press release prior to the call.

ROCHESTER, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, provides a 2023 mid-year strategic update commenting on: 1) current revenue backlog, 2) strategic roadmap with key pillars of growth, and 3) long term financial performance aspirations through steady buildout of scalable, future proofed, enterprise solution suite.

Castagna was recognized as a Digital Crusader for her ongoing and leading-edge work in digital access to therapies for patients

ROCHESTER, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following upcoming investor conferences: 

ROCHESTER, Mich., May 10, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2023. Quarterly comparisons are to the same year-ago period.

Physicians report that they are encountering brand information across multiple digital and in-person channels, yet still lack key information on patient eligibility, affordability, and access

ROCHESTER, Mich., April 26, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2023. The financial results will be issued in a press release prior to the call.

ROCHESTER, Mich., April 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy has published its 2023 Environmental, Social and Governance (ESG) report.

– AI driven RWD deals grow from 6 completed in 2022 to several dozen in pipeline today, representing the rapid adoption of OptimizeRx’s health technology enablement platform services

ROCHESTER, Mich., March 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $15 million of its outstanding common stock.

Deal will enable high-growth patient services company to streamline and enhance its services with OptimizeRx’s technology solutions

ROCHESTER, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022.

ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and fiscal year, ended December 31, 2022. The financial results will be issued in a press release prior to the call.

ROCHESTER, Mich., Feb. 09, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its senior vice president of access and adherence, Karina Castagna, has been named to MM+M’s 40 Under 40 List for her accomplishments and contributions to the healthcare marketing industry.

ROCHESTER, Mich., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy announced OptimizeRx’s CEO Will Febbo is invited to speak at the upcoming J.P. Morgan Healthcare Conference. The OPRX conference presentation is scheduled to begin at 8:15 AM PT on January 12, 2023. Ahead of the conference, OPRX is providing the following business update and key industry trends from management’s presentation.

ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following upcoming investor conferences: 

ROCHESTER, Mich., Nov. 08, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended September 30, 2022. Quarterly comparisons are to the same year-ago period.

Virtual event takes place December 1, 2022

ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time to discuss its results for the third quarter, ended September 30, 2022. The financial results will be issued in a press release prior to the call.

Analysis demonstrates effectiveness of OptimizeRx’s real-world evidence solution to identify patients suitable for a specialty therapy within a narrow timeframe

Healthcare advertising agencies can now easily add retail pharmacies to their healthcare media buying strategies